CARB-X

CARB-X announced Tuesday an award of up to $3.6 million (plus up to $10.2 million in milestones) to Maryland-based Novel Microdevices to develop a rapid, point-of-care, battery-powered diagnostic for sexually transmitted infections such as chlamydia and gonorrhea.

The test—which will also identify antibiotic resistance—will diagnose infections in about 25 minutes from a vaginal swab or urine sample and require no sample preparation, making it “particularly suited” for LMICs, according…

CARB-X announced Monday an award of up to $2 million and up to $5.3 million more in milestones to the University of Oxford’s Jenner Institute for work on its gonorrhea vaccine candidate (dmGC_0817560 NOMV), currently in lead optimization.

The funds will support optimization, scale-up and production for first-in-human trials of “an affordable vaccine for global use,” the press release said.

CARB-X published compulsory guidance on Monday to ensure that new antibacterial products brought to market by its funded companies are used responsibly and made available to people in LMICs.

The Stewardship and Access Plan Development Guide—created by the Boston University-led nonprofit and its partners, including the Access to Medicine Foundation, the Gates Foundation, the Global Antibiotic Research and Development Partnership, the Global Antimicrobial Resistance Innovation Fund, and…

The U.S. National Institute of Allergy and Infectious Diseases (NIAID) announced on Thursday that it has awarded a total of $2.5 million in grants to 12 institutes to support research on bacteriophage therapy as a potential strategy to combat antibacterial resistance.

In other AMR news, New York-based ContraFect announced Thursday an award from the U.S. Biomedical Advanced Research and Development Authority of $9.8 million upfront and up to $77 million in milestones to fund Phase 3…

CARB-X committed up to $3.5 million to Affinivax to support the Massachusetts-based biotech’s development of a new vaccine to prevent Staphylococcus aureus infections, according to a CARB-X press release on Tuesday.

The Boston University-led nonprofit may add up to $18.5 million to the award if the vaccine—which will use the company’s Multiple Antigen Presenting System to include a variety of staphylococcal protein antigens—reaches certain milestones.

CARB-X announced two awards on Monday to GSK Biologicals and the GSK Vaccines Institute for Global Health to fund two vaccines currently in preclinical development: one to prevent Group A Streptococcus infections and the other targeting Salmonella enterica. The awards are potentially worth more than $18 million, according to a CARB-X press release.

GSK also received up to $7.5 million from CARB-X in September 2020 to fund a Phase 1 trial of an E. coli drug—the Boston University-led…

CARB-X announced on Tuesday up to $2.2 million in funding for the University of Queensland’s octapeptin potentiator research program, which aims to develop a new drug that disables the protective cell membrane of drug-resistant Gram-negative bacteria.

Low- and middle-income countries could use engineered octapeptin peptides to “breathe new life” into old antibiotics, according to the press release.

Mentions:

CARB-X announced two new investments in the first days of February.

The Boston University-led nonprofit will award up to $12.2 million to France’s Mutabilis to develop a new intravenous drug to treat infections caused by carbapenem-resistant Enterobacterales (CRE) bacteria.

CARB-X will also invest up to $17.2 million in California-based diagnostics specialist Avails Medical to fund the company’s high-speed electronic antibiotic-susceptibility testing device for blood infections…

CARB-X announced Wednesday an award of up to $13.6 million to fund Lumen Bioscience’s investigational oral monoclonal antibody cocktail for the prevention of diarrheal diseases caused by C. jejuni and E. coli.

Lumen hopes to produce a “food-grade immuno-prophylactic drug at low cost” suitable for use worldwide, including in areas lacking temperature control for health products, according to the CARB-X press release.

CARB-X announced two new investments on Tuesday. The first, worth up to $8.77 million, will go to Germany’s Helmholtz Centre for Infection Research (HZI) and the Dortmund-based Lead Discovery Center to develop a drug to prevent S. aureus-induced lung tissue damage in pneumonia patients. The second award—up to $6.31 million to a team of HZI-affiliated researchers—will fund the development of a new treatment for P. aeruginosa infections in cystic fibrosis patients.

In other news, the…

Mentions: